ALPS Medical Breakthroughs ETF
SBIO
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S-Network Medical Innovation Index. The fund invests at least 80% of its net assets in securities comprising the index, which consists of U.S.-listed companies in the biotechnology and pharmaceutical industries that are engaged in Phase II or Phase III clinical trials for breakthrough therapies designated by the U.S. Food and Drug Administration; such securities include common stocks, American Depositary Receipts, and tracking stocks. SBIO offers investors targeted exposure to innovative medical companies advancing novel treatments for serious unmet medical needs, with holdings diversified across sub-sectors such as oncology, rare diseases, infectious diseases, and neurology; notable portfolio categories encompass small-cap biotech firms developing antibody-drug conjugates, gene therapies, cell therapies, and small molecule inhibitors. The ETF is issued and managed by ALPS Distributors, Inc., part of the ALPS Funds family under SS&C Technologies Holdings, Inc., and was launched in May 2015 with headquarters operations based in Denver, Colorado; it primarily targets U.S. institutional and retail investors focused on thematic healthcare equity strategies. In recent developments, SBIO benefited from heightened investor interest in biotech amid 2024-2025 clinical trial successes and FDA approvals for several index constituents, alongside ALPS ETF Services' enhancements to index tracking methodologies and portfolio rebalancing protocols in late 2024 to improve liquidity and reduce tracking error; no major acquisitions or name changes were reported for the fund itself during this period.